GlassScriptPhysician profile
Danielle M Stevenson
NPI 1760169114
$6,143.79
in general payments reported to CMS, 2019-2025
53 companies · $3,957 in 2025
The $3,957 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $483 · 2024: $1,704 · 2025: $3,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,044 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,043.80 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $833.90 | 2023-2025 | Enhertu, Tagrisso, Imfinzi |
| Novartis Pharmaceuticals Corporation | $425.33 | 2024-2025 | |
| Daiichi Sankyo INC. | $413.91 | 2024-2025 | Enhertu, Datroway |
| Genzyme Corporation | $392.06 | 2023-2025 | |
| Eisai INC. | $369.51 | 2024-2025 | |
| Janssen Biotech, INC. | $324.17 | 2023-2025 | Darzalex, Tecvayli, Carvykti |
| Merck Sharp & Dohme LLC | $303.56 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Glaxosmithkline, LLC. | $233.55 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Celgene Corporation | $187.47 | 2023-2025 | Reblozyl, Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $175.50 | 2023-2025 | Ninlaro, Fruzaqla, Vpriv |
| E.R. Squibb & Sons, L.L.C. | $160.77 | 2023-2025 | Opdivo |
| Emd Serono, INC. | $158.05 | 2024-2025 | |
| Pfizer INC. | $153.48 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.56 | 2023-2025 | |
| Sirtex Medical INC | $141.72 | 2025 | Sir-Spheres Microspheres |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.